119 related articles for article (PubMed ID: 38403350)
21. Relationship between long non-coding RNA PCAT-1 expression and gefitinib resistance in non-small-cell lung cancer cells.
Wang S; Liu C; Lei Q; Wu Z; Miao X; Zhu D; Yang X; Li N; Tang M; Chen Y; Wang W
Respir Res; 2021 May; 22(1):146. PubMed ID: 33980216
[TBL] [Abstract][Full Text] [Related]
22. Combined treatment with N-acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line.
Li J; Wang XH; Hu J; Shi M; Zhang L; Chen H
Cancer Med; 2020 Feb; 9(4):1495-1502. PubMed ID: 31891230
[TBL] [Abstract][Full Text] [Related]
23. Inhibitor of ghrelin receptor reverses gefitinib resistance in lung cancer.
Li X; Zhao X; Li C; Liu S; Yan F; Teng Y; Feng J; Miao D
Hum Cell; 2019 Jul; 32(3):360-366. PubMed ID: 31020605
[TBL] [Abstract][Full Text] [Related]
24. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201
[TBL] [Abstract][Full Text] [Related]
25. CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo.
Zhang K; Wang L; Wei A; Jia X; Liu X
Thorac Cancer; 2020 Jun; 11(6):1566-1577. PubMed ID: 32368855
[TBL] [Abstract][Full Text] [Related]
26. YC-1 potentiates the antitumor activity of gefitinib by inhibiting HIF-1α and promoting the endocytic trafficking and degradation of EGFR in gefitinib-resistant non-small-cell lung cancer cells.
Hu H; Miao XK; Li JY; Zhang XW; Xu JJ; Zhang JY; Zhou TX; Hu MN; Yang WL; Mou LY
Eur J Pharmacol; 2020 May; 874():172961. PubMed ID: 32044322
[TBL] [Abstract][Full Text] [Related]
27. Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells.
Wang YQ; Shen AJ; Sun JY; Wang X; Liu HC; Zhang MM; Chen DQ; Xiong B; Shen JK; Geng MY; Zheng M; Ding J
Acta Pharmacol Sin; 2016 Dec; 37(12):1587-1596. PubMed ID: 27616574
[TBL] [Abstract][Full Text] [Related]
28. Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
Yang J; Qin G; Luo M; Chen J; Zhang Q; Li L; Pan L; Qin S
Cell Death Dis; 2015 Jul; 6(7):e1829. PubMed ID: 26203858
[TBL] [Abstract][Full Text] [Related]
29. Yang-Yin-Jie-Du decoction overcomes gefitinib resistance in non-small cell lung cancer via down-regulation of the PI3K/Akt signalling pathway.
Chen SY; Zhang GC; Shu QJ
Pharm Biol; 2021 Dec; 59(1):1294-1304. PubMed ID: 34543169
[TBL] [Abstract][Full Text] [Related]
30. GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway.
Wang L; Liu J; Liu J; Chen X; Chang M; Li J; Zhou J; Bai C; Song Y
J Cancer Res Clin Oncol; 2019 Apr; 145(4):861-872. PubMed ID: 30661098
[TBL] [Abstract][Full Text] [Related]
31. Omega-3 Fatty Acid-Enriched Fish Oil and Selenium Combination Modulates Endoplasmic Reticulum Stress Response Elements and Reverses Acquired Gefitinib Resistance in HCC827 Lung Adenocarcinoma Cells.
Liao CH; Tzeng YT; Lai GM; Chang CL; Hu MH; Tsai WL; Liu YR; Hsia S; Chuang SE; Chiou TJ; Wang LM; Whang-Peng J; Yao CJ
Mar Drugs; 2020 Jul; 18(8):. PubMed ID: 32751169
[TBL] [Abstract][Full Text] [Related]
32. FZKA reverses gefitinib resistance by regulating EZH2/Snail/EGFR signaling pathway in lung adenocarcinoma.
Tang Q; Xu M; Long S; Yu Y; Ma C; Wang R; Li J; Wang X; Fang F; Han L; Wu W; Wang S
J Ethnopharmacol; 2024 Jan; 318(Pt A):116646. PubMed ID: 37269912
[TBL] [Abstract][Full Text] [Related]
33. FBP1 induced by β-elemene enhances the sensitivity of gefitinib in lung cancer.
Li J; Dai P; Sun J; Yu W; Han W; Li K
Thorac Cancer; 2023 Feb; 14(4):371-380. PubMed ID: 36525508
[TBL] [Abstract][Full Text] [Related]
34. Co-treatment of betulin and gefitinib is effective against EGFR wild-type/KRAS-mutant non-small cell lung cancer by inducing ferroptosis.
Yan WY; Cai J; Wang JN; Gong YS; Ding XB
Neoplasma; 2022 May; 69(3):648-656. PubMed ID: 35330996
[TBL] [Abstract][Full Text] [Related]
35. Krüppel-like factor 4 promotes c-Met amplification-mediated gefitinib resistance in non-small-cell lung cancer.
Feng W; Xie Q; Liu S; Ji Y; Li C; Wang C; Jin L
Cancer Sci; 2018 Jun; 109(6):1775-1786. PubMed ID: 29624806
[TBL] [Abstract][Full Text] [Related]
36. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET.
Oh HN; Lee MH; Kim E; Yoon G; Chae JI; Shim JH
Phytomedicine; 2019 Oct; 63():153014. PubMed ID: 31323446
[TBL] [Abstract][Full Text] [Related]
37. Clathrin-mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild-type EGFR non-small cell lung cancer.
Kim B; Park YS; Sung JS; Lee JW; Lee SB; Kim YH
Cancer Med; 2021 Jan; 10(1):372-385. PubMed ID: 33314735
[TBL] [Abstract][Full Text] [Related]
38. Butein, a novel dual inhibitor of MET and EGFR, overcomes gefitinib-resistant lung cancer growth.
Jung SK; Lee MH; Lim DY; Lee SY; Jeong CH; Kim JE; Lim TG; Chen H; Bode AM; Lee HJ; Lee KW; Dong Z
Mol Carcinog; 2015 Apr; 54(4):322-31. PubMed ID: 24974831
[TBL] [Abstract][Full Text] [Related]
39. BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells.
Yu Y; Xiao Z; Lei C; Ma C; Ding L; Tang Q; He Y; Chen Y; Chang X; Zhu Y; Zhang H
BMC Cancer; 2023 Aug; 23(1):732. PubMed ID: 37553597
[TBL] [Abstract][Full Text] [Related]
40. Functional cooperation between HIF-1α and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR.
Meng S; Wang G; Lu Y; Fan Z
Lung Cancer; 2018 Jul; 121():82-90. PubMed ID: 29858032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
